Brief: US FDA Approves Trutakna For Proteinuria In Primary Immunoglobulin A Nephropathy
07/07/2026 18:14
BRIEF-US FDA Approves Trutakna For Proteinuria In Primary Immunoglobulin A Nephropathy July 7 (Reuters) - US FDA:
US FDA - APPROVES TRUTAKNA FOR PROTEINURIA IN PRIMARY IMMUNOGLOBULIN A NEPHROPATHY
Further company coverage: VERA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vera Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Sysco
Vera Therapeutics gains after kidney disease drug meets goals in confirmatory trial